Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [3] - Ardelyx's pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas [3] Upcoming Conference Call - Ardelyx will hold a conference call on February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update for the full year and fourth quarter of 2025 [1] - The call will feature commentary from key members of the Ardelyx Executive Leadership Team, including the President and CEO, CFO, Chief Commercial Officer, and Chief Patient Officer [1] Commercialization Agreements - Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S., including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] - Knight Therapeutics is responsible for commercializing IBSRELA in Canada [3]